OUR TEAM
Board of Directors
Chief Executive Officer
Mr. Carlton is an experienced leader in the medical device industry. In addition to his role as CEO at EBT Medical, he is Co-founder and General Partner at Guide Medical Ventures, a seed investment and management consulting firm focusing on companies in the medical device space. Prior to his role at EBT Medical, he was President and CEO of HUINNO Inc., a digital healthcare company focused on improving the management and cost of hypertension through wearable technology and software.
Mr. Carlton came to Boston Scientific via the acquisition of Intelect Medical, where he served as both Co-Founder and Vice President of Product Development. While at Boston Scientific Neuromodulation, Mr. Carlton held multiple positions including Director of New Therapy Development where he focused on pain, deep brain stimulation, overactive bladder, and more.
At the start of his career, he held various roles at Medtronic, co-inventing the InterStim™ tined lead and developing InterStim™ II for the treatment of overactive bladder. He also served as Director of Engineering at Texcel Medical (Cirtec Medical).
Holding over 50 patents around electrical stimulations products and therapies, Mr. Carlton has a dual BS in Biomedical Engineering and Engineering Mechanics from The John Hopkins University. He also holds an MBA from Boston University.
Co-Founder SPRIM and CEO of ObvioHealth
Mr. Jarry is an entrepreneur and executive in the life sciences and digital health sectors with more than two decades of experience building and scaling global healthcare organizations. He is the Founder and Chief Executive Officer of ObvioHealth, Founder and Managing Partner of Sprim Global Investments, Director of SPRIM PRO, and a Board Member of RegAsk and Clerkenwell Health.
Mr. Jarry is a Co-Founder of SPRIM, a global life sciences consulting and investment organization established in 2001. Through Sprim Global Investments, the firm’s venture creation and investment platform, he has helped launch and scale numerous companies across the healthcare innovation ecosystem, spanning digital health, clinical research, biotechnology, and regulatory technology. Over the past two decades, he has worked with pharmaceutical, biotechnology, and consumer health companies worldwide on strategy, innovation, and evidence generation while supporting the creation and growth of early-stage healthcare ventures.
In 2017, Mr. Jarry founded ObvioHealth to address inefficiencies in traditional clinical trials by leveraging mobile technologies, data integration, and patient-centric design. Under his leadership, the company has developed a global virtual research organization and enterprise software platform supporting decentralized and hybrid clinical trials, enabling sponsors to run more efficient, accessible, and data-rich clinical research programs.
Over the course of his career, Mr. Jarry has been involved in the creation and growth of more than 40 companies across the healthcare innovation ecosystem, ranging from consulting firms and CROs to digital health and biotechnology ventures. A global entrepreneur who has lived and worked across North America, Europe, and Asia-Pacific, he brings extensive experience in scaling organizations, structuring strategic partnerships, and supporting global governance through board and advisory roles across the life sciences innovation ecosystem.
Board Observer, Co-Founder and Chief Innovation Officer
Dr. John is an inventor, scientist, and entrepreneur with 35+ years of experience developing and commercializing innovative medical and computer technologies. He is the sole inventor on the first patents for statistical, closed-loop neurostimulation (licensed into NeuroPace’s FDA-approved epilepsy therapy), and a co-inventor of an EEG-based audiometry technology acquired by Bio-logic Systems Corp. that became the company’s best-selling product prior to its acquisition by Natus.
He holds over 130 U.S. patents and has advised on IP strategy in areas of implantable and transcranial neurostimulation, neurodiagnostics, digital health, wireless power transmission, and renal nerve ablation. As Chief Scientific Officer of Avertix Medical, he helped secure FDA approval for the world’s first implantable heart-attack detector and led initiatives in clinical trial design and market access strategy. He received a B.A. in Psychology from Reed College, an M.Sc. in Psychiatry from McGill University, and a Ph.D. in Medical Science from the University of Toronto.
Managing Partner, SV Health Investors
Mr. Madden joined SV in 2002 as an Analyst and later transitioned to the role of Portfolio Manager with both portfolio and lead fundraising responsibilities. Following business school, he was promoted to Principal and became Partner in 2018.
Mr. Madden is focused on medical device and healthcare services investments and is actively engaged in the financing, strategy, operations and acquisitions of portfolio companies. His active investments include AcuFocus, BardyDx, CardioFocus, CSA Medical, Endotronix, Leiters, Solsys Medical (now Misonix (NASDAQ: MSON), Stimwave, and Ximedica.
Prior to SV, Mr. Madden worked at Testa, Hurwitz & Thibeault, in the Business Practice, Emerging Technology and Private Equity groups, supporting both venture capital funds and venture backed companies in business formations and financings, mergers and acquisitions, and venture capital fundraising. He holds a BA (with honors) from Colby College, and an MBA from Boston University (Beta Gamma Sigma).
Operating Partner SV Health Investors
Since 2020, Tom Patton has been an Operating Partner at SV Health Investors, a healthcare focused private equity group. Tom is an experienced med-tech CEO and Board member with a 25-year record of creating value for private equity and public shareholders. In addition to his Board role at EBT, Tom currently is the Executive Chairman of Spineology, and is on the Board of Miach Orthopedics, Robling Medical and Packaging Compliance Labs. Tom also serves on the Board of ElectroCore (NASD: ECOR) and of the Connecticut Port Authority as an appointee of Governor Lamont.
Tom has extensive operating experience in the med-tech space, leading five different companies as CEO until their sale, including Ximedica, CASMED (NASD: CASM),QDx, Novametrix (NASD: NMTX) and Wright Medical. Tom has extensive Board experience having served on the Board of more than a dozen public and private companies. Tom started his career as a litigator at the law firm of Williams and Connolly in Washington DC, thereafter joining Wright Medical as its General Counsel.
He earned a BA from The College of the Holy Cross, and a JD, magna cum laude, from Georgetown University Law Center.
He is currently an adjunct Professor of Entrepreneurship at Holy Cross.
Co-Founder & Managing Partner, Ignite Venture Studio
Mr. Smith is co-founder and managing partner of Ignite Venture Studio, which develops brands to disrupt the ‘startup-quo’ by building and accelerating their performance to achieve success in collaboration with strategic partners. Additionally, he recently launched HONED™️ Vitamins, a subscription service personalized through metabolic testing, and Fluent Smart Exam™️, a first oto market device that make sit simple to conduct medical exams remotely and share them with a virtual care physician via your smartphone.
Before founding Ignite Venture Studios, Mr. Smith served the majority of his career in various senior leadership roles at Johnson & Johnson, the world’s largest and most diversified healthcare company. Most recently, he served as Company Group Chairman, North America and oversaw several divisions and brands including Tylenol®, Zyrtec®, Band-Aid Brand®, and Neutrogena®.
During his time at J&J, he developed a strong track record of building and marketing global brands, driving insight-driven innovations, leading strategic business turnarounds, and delivering profitable growth.
Professor Yoo has spent nearly 3 decades researching diverse areas of peripheral nerve stimulation therapies, such as neural control of lower urinary function, obstructive sleep apnea, and chronic heart failure.
In addition to academic research, Dr. Yoo has worked on a number of projects within the medical device space working with such companies as Imthera Medical Inc, Microtransponder Inc., Ethicon Endosurgery, Boston Scientific Corporation, and Nuviant Medical.
Prior to joining the University of Toronto in 2012, Dr. Yoo worked both as a post-doctoral research associate and assistant research professor at Duke University under Warren Grill. Dr. Yoo received his BASc from the University of Toronto in Engineering Science (Biomedical Option), MS in Biomedical Engineering from the University of Southern California, and PhD from Case Western Reserve University in Biomedical Engineering.